January 12, 2017
Celyad: First pancreatic cancer patient in its CAR-T NKR-2THINK trial in Belgium
Celyad has activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
January 11, 2017
Eli Lilly, Merck expand collaboration against cancer
Eli Lilly and Merck have expand an existing immuno-oncology collaboration through a subsidiary to add a new study of Lilly’s…
January 11, 2017
Evgen Pharma gets positive DSMB review of SAS trial
Evgen Pharma’s anti-stress drug SFX-01, which is currently in its Phase II study has shown good results and it can proceed as planned.
January 11, 2017
ValiRx encouraged by initial trials of cancer drug study, expands to more sites
A clinical stage biotechnology company, ValiRX, said on Wednesday that its VAL201 personalised Phase l/II prostate cancer study brought positive results.
January 11, 2017
Premaitha closes deal on Yourgene acquisition
Premaitha Health’s shareholders have approved the acquisition of Yourgene, a bioinformatics specialist based in Taiwan. The purchase was approved on Tuesday afternoon.
January 11, 2017
Director Jonathan Freeman’s Dealings
Futura Medical, the innovative healthcare company focused on advanced transdermal technology has been notified that on 10 January 2017, Jonathan…
January 11, 2017
UPDATE: Omega starts selling malaria tests in India
Food allergy focused medical diagnostic company Omega has gotten ISO certification for the Quality Management System for its Asian subsidiary in India, and it started with the domestic sales of its products.
January 11, 2017
Genfit: half-year report of liquidity contract with CIC
GENFIT, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that affect the liver…
January 11, 2017
FDA calls for more patient enrollments
The U.S. Food and Drug Administration (FDA) has noticed that lately for certain reason, there are fewer number of people willing to participate in clinical trials for different medications. Therefore, it has decided to encourage patients to take a part in helping researching companies to develop new drugs.
January 10, 2017
Japanese Takeda in a $5.2 billion acquisition deal with USA-based Ariad
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.